TD Cowen reiterated a Buy rating for Boston Scientific (NYSE:BSX) stock, maintaining a price target of $110.00. The stock, currently trading at $98.78, has shown remarkable momentum, reaching new ...

In a report released today, Josh Jennings from TD Cowen maintained a Buy rating on Boston Scientific (BSX – Research Report), with a price ...

Boston Scientific stock popped Wednesday after the medtech giant agreed to full acquire Bolt Medical for up to $900 million.

With Watchman, Boston Scientific estimates a 20% compound annual growth rate (CAGR) in 2025 with a high market share. Mahoney ...

The most recent trading session ended with Boston Scientific (BSX) standing at $98.66, reflecting a +0.5% shift from the previouse trading day's closing. The stock lagged the S&P 500's daily gain of 1 ...

Morgan Stanley analyst Patrick Wood maintained a Buy rating on Boston Scientific (BSX – Research Report) today and set a price target of ...

Boston Scientific (NYSE: BSX) today reported data from separate studies backing its Farapulse and Watchman FLX systems.

Boston Scientific outperforms competitors with strong growth in atrial fibrillation devices and recent acquisitions. Learn ...

At the J.P. Morgan Healthcare Conference, Boston Scientific forecast that pulsed field ablation will be used in more than 60% of atrial fibrillation procedures globally by 2026.

This was the stock's second consecutive day of losses.

Boston Scientific (BSX) reachead $91.99 at the closing of the latest trading day, reflecting a +0.77% change compared to its last close.

Beyond technological innovations and effectiveness, a key factor is its cost-reduction approach to its products, enabling greater adoption by the medical community. Boston Scientific has performed ...